Prostate cancer (PC), often referred to as a cold tumor, typically presents a poor immune response, making it difficult for immune-based therapies to be effective. Metastatic castration-resistant PC (mCRPC) presents a highly aggressive phenotype often refractory to systemic treatment.

Harbour Biomed Ltd. has announced the launch of Élancé Therapeutics with an aim to improve the treatment of obesity. Élancé seeks to address challenges in obesity treatment, by increasing overall body weight loss and fat mass loss, while preserving and even increasing muscle and lean mass.